Proper foot care can help prevent many complications associated with this condition.
American Diabetes Month is a good time to highlight the sobering statistics of this widespread disease.
Providing medication therapy management (MTM) for patients with diabetes presents many challenges.
This system provides rapid results without the use of venipuncture.
This device is the only continuous glucose monitor approved for patients aged 2 to 17 years.
Patients with diabetes often experience foot complications, such as ulcers, infections, and even amputations.1
Through screening for early detection of cognitive impairment and dementia, patients have a better chance of managing their diabetes at home with provider assistance.
In this innovative practice model, pharmacists collaborate with women's health providers to educate patients.
Diabetic peripheral neuropathy is present in up to 10% of type 2 diabetes mellitus patients upon initial diagnosis.
According to the American Diabetes Association (ADA), 60% to 70% of diabetes patients develop peripheral nerve damage.
This sensor-augmented pump monitors moment-to-moment glucose changes.
Self-monitoring of blood glucose is an important part of modern therapy for diabetes mellitus.
This novel medication for treatment of type 2 diabetes
provides an alternative for patients who are not well controlled on
current drug therapy or diet and exercise.
The device measures blood glucose readings every 5 minutes for 7 days.
Although it is not entirely clear why
diabetes causes nerve damage, it is thought to be a result of poorly
controlled blood glucose over a long period of time.
Metabolic consequences of antipsychotic use include weight gain, hyperglycemia, and dyslipidemia.
Young adults with diabetes
are at increased risk for developing psychiatric comorbidities,
including eating disorders, because of the complex nature of chronic
disease management as well as the effects of chronic disease on
Community pharmacists can play an integral role in educating patients
about foot care and in recognizing ulcers that can lead to skin
infections such as cellulitis.
Beyond weight management, these procedures may induce remission of T2DM.
Regular ophthalmic screenings help reduce the risk of this progressive eye disease.
Management of metabolic complications, including diabetes mellitus and metabolic syndrome, in the psychiatric patient is complex.
Based on evolving clinical evidence, the American Diabetes Association modified
primary-prevention aspirin recommendations in 2010 to encompass only
patients with a 10-year cardiovascular risk greater than 10%.
Counseling, infection control, and treatment, all of which pharmacists
are trained to perform, are of paramount importance.
A major health insurance company and pharmacy chain have partnered to offer patients with type 2 diabetes access to a new diabetes control program.
Gestational diabetes mellitus (GDM) is defined as any degree of glucose intolerance that occurs with pregnancy or is first discovered during pregnancy. GDM, which is the most common metabolic complication associated with pregnancy, imposes risks on both mother and fetus.
By optimizing medication use and reducing the risks of polypharmacy, the pharmacists plays a key role in decreasing morbidity and mortality in this patient population.
In the United States, the number of people diagnosed with diabetes is staggering.
Peripheral neuropathy (PN) is one of the most common complications of diabetes.
T ype 2 diabetes mellitus (DM2) results from the combination of an insulin-secretory defect and peripheral insulin resistance.
T he American Diabetes Association (ADA) defines diabetes mellitus as a group of metabolic diseases characterized by hyperglycemia resulting from defects in insulin secretion, insulin action, or both.
Researchers at Duke University have discovered that caffeine taken in even moderate doses could impair glucose control in patients with type 2 diabetes.
Currently, there are 20.8 million people, or 7% of the U.
Diabetes mellitus (DM) currently affects an estimated 20.8 million people within the United States, with a current worldwide prevalence estimated at 180 million and which is expected to double by 2030.
Diabetes is a major public health problem that affects 7% of the United States population, or 20.8 million people.
Omega-3 Fatty Acids Reduce Risk of Type 1 Diabetes in Children Preliminary research published in a recent issue of JAMA suggests that the dietary intake of omega-3 fatty acids by children at increased genetic risk for type 1 diabetes is associated with a reduced risk of pancreatic islet autoimmunity, which is linked to the development of this disease.
Diabetes is the fifth leading cause of death worldwide.